Why was the cancer-causing protein KRas historically considered 'undruggable', according to the article?

According to the article, KRas was once considered undruggable because it is 'compact, lacks the deep crevices that drugs might bind to, and mutates frequently.' These structural and dynamic properties made it extremely difficult for traditional small-molecule drugs to achieve stable, high-affinity binding—key requirements for effective inhibition.

What pivotal event in 2018 enabled Revolution Medicines to advance its work on KRas, and how did Jim Cregg contribute despite being a junior scientist?

In 2018, Revolution Medicines acquired Warp Drive Bio, which had been developing small molecules targeting a protein-folding chaperone with a smooth drug target—KRas being 'the perfect example' of such a target. Though Jim Cregg was 'just a junior scientist' at the time, he was assigned to the team tasked with integrating Warp Drive’s chaperone-targeting approach with RevMed’s existing programs—a critical step in marrying complementary strategies to tackle KRas.

Revolution Medicines Chemist Jim Cregg on Targeting Undruggable KRas

May 13, 2026

Revolution Medicines chemist Jim Cregg discusses his work targeting the undruggable KRas protein following the company's acquisition of Warp Drive Bio. His research focuses on developing small molecules to treat cancer by binding protein-folding chaperones.

cen

2026-05-13

Revolution Medicines Chemist Jim Cregg on Targeting Undruggable KRas

FAQ

Scan to get the App